Themis Medicare Limited (THEMISMED.BO)
INR 273.3
(0.64%)
INR 273.3
(0.64%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.5 Billion INR | -35.55% |
| 2022 | 2.33 Billion INR | -3.83% |
| 2021 | 2.42 Billion INR | 61.6% |
| 2020 | 1.5 Billion INR | 9.82% |
| 2019 | 1.36 Billion INR | 19.68% |
| 2018 | 1.14 Billion INR | -16.31% |
| 2017 | 1.36 Billion INR | -5.56% |
| 2016 | 1.44 Billion INR | -0.2% |
| 2015 | 1.44 Billion INR | 32.5% |
| 2014 | 1.09 Billion INR | 0.69% |
| 2013 | 1.08 Billion INR | 17.58% |
| 2012 | 923.2 Million INR | 57.97% |
| 2011 | 584.43 Million INR | 27.47% |
| 2010 | 458.48 Million INR | 43.49% |
| 2009 | 319.51 Million INR | 382.26% |
| 2008 | 66.25 Million INR | -78.84% |
| 2007 | 313.14 Million INR | 27.69% |
| 2006 | 245.24 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 753.75 Million INR | -15.89% |
| 2024 Q1 | 577.22 Million INR | 74.52% |
| 2023 Q2 | 628.43 Million INR | -7.01% |
| 2023 Q3 | 560.3 Million INR | -10.84% |
| 2023 Q4 | 330.75 Million INR | -40.97% |
| 2023 FY | 1.5 Billion INR | -35.55% |
| 2023 Q1 | 675.78 Million INR | 36.05% |
| 2022 Q4 | 496.72 Million INR | -10.25% |
| 2022 Q1 | 648.26 Million INR | 31.77% |
| 2022 FY | 2.33 Billion INR | -3.83% |
| 2022 Q2 | 634.81 Million INR | -2.08% |
| 2022 Q3 | 553.45 Million INR | -12.82% |
| 2021 Q4 | 491.97 Million INR | -12.52% |
| 2021 Q1 | 709.91 Million INR | 81.97% |
| 2021 FY | 2.42 Billion INR | 61.6% |
| 2021 Q2 | 661.88 Million INR | -6.77% |
| 2021 Q3 | 562.41 Million INR | -15.03% |
| 2020 Q4 | 390.12 Million INR | -9.08% |
| 2020 Q3 | 429.09 Million INR | 17.09% |
| 2020 FY | 1.5 Billion INR | 9.82% |
| 2020 Q1 | 315.68 Million INR | -13.0% |
| 2020 Q2 | 366.46 Million INR | 16.08% |
| 2019 Q2 | 316.32 Million INR | -5.72% |
| 2019 Q4 | 362.83 Million INR | 2.93% |
| 2019 Q1 | 335.5 Million INR | 59.77% |
| 2019 FY | 1.36 Billion INR | 19.68% |
| 2019 Q3 | 352.51 Million INR | 11.44% |
| 2018 Q3 | 287.35 Million INR | -7.75% |
| 2018 Q2 | 311.5 Million INR | -6.58% |
| 2018 Q1 | 333.45 Million INR | -10.95% |
| 2018 FY | 1.14 Billion INR | -16.31% |
| 2018 Q4 | 209.99 Million INR | -26.92% |
| 2017 Q4 | 374.44 Million INR | 5.98% |
| 2017 FY | 1.36 Billion INR | -5.56% |
| 2017 Q2 | 352.35 Million INR | 0.0% |
| 2017 Q3 | 353.32 Million INR | 0.28% |
| 2016 Q3 | 344.62 Million INR | -9.91% |
| 2016 FY | 1.44 Billion INR | -0.2% |
| 2016 Q2 | 382.55 Million INR | -8.83% |
| 2016 Q1 | 419.58 Million INR | 21.09% |
| 2016 Q4 | 366.81 Million INR | 6.44% |
| 2015 Q1 | 347.61 Million INR | 15.49% |
| 2015 Q3 | 366.3 Million INR | -7.04% |
| 2015 Q4 | 346.5 Million INR | -5.4% |
| 2015 FY | 1.44 Billion INR | 32.5% |
| 2015 Q2 | 394.03 Million INR | 13.36% |
| 2014 Q3 | 208.05 Million INR | -24.35% |
| 2014 FY | 1.09 Billion INR | 0.69% |
| 2014 Q2 | 275.02 Million INR | 0.0% |
| 2014 Q4 | 300.99 Million INR | 44.67% |
| 2013 FY | 1.08 Billion INR | 17.58% |
| 2012 Q1 | 71.28 Million INR | 0.0% |
| 2012 FY | 923.2 Million INR | 57.97% |
| 2012 Q3 | 53.7 Million INR | -51.75% |
| 2012 Q2 | 111.29 Million INR | 56.13% |
| 2012 Q4 | 682.11 Million INR | 1170.11% |
| 2011 FY | 584.43 Million INR | 27.47% |
| 2010 FY | 458.48 Million INR | 43.49% |
| 2009 FY | 319.51 Million INR | 382.26% |
| 2008 FY | 66.25 Million INR | -78.84% |
| 2007 FY | 313.14 Million INR | 27.69% |
| 2006 FY | 245.24 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Ajanta Pharma Limited | 21.06 Billion INR | 92.86% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | 3.381% |
| Sigachi Industries Limited | 2 Billion INR | 24.891% |
| Bal Pharma Limited | 770.19 Million INR | -95.263% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 75.721% |
| Medico Remedies Limited | 262.14 Million INR | -473.694% |
| Lasa Supergenerics Limited | 121.02 Million INR | -1142.588% |
| Venus Remedies Limited | 2.18 Billion INR | 31.095% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 349.65% |
| Alpa Laboratories Limited | 188.89 Million INR | -696.159% |
| Nectar Lifesciences Limited | 2.97 Billion INR | 49.399% |
| Shilpa Medicare Limited | 3.54 Billion INR | 57.599% |
| Aarti Drugs Limited | 8.31 Billion INR | 81.916% |
| Lupin Limited | 123.71 Billion INR | 98.784% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 99.028% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 98.799% |
| Windlas Biotech Limited | 1.33 Billion INR | -12.332% |
| Suven Life Sciences Limited | -200.79 Million INR | 848.967% |
| Eris Lifesciences Limited | 10.42 Billion INR | 85.577% |
| Valiant Laboratories Limited | -60.66 Million INR | 2579.072% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 93.375% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -74.629% |
| Ipca Laboratories Limited | 29.8 Billion INR | 94.955% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 59.304% |
| Achyut Healthcare Limited | 4.86 Million INR | -30838.161% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.418% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -2.181% |
| RPG Life Sciences Limited | 2.48 Billion INR | 39.432% |
| Mankind Pharma Limited | 44.52 Billion INR | 96.622% |
| Laurus Labs Limited | 24.62 Billion INR | 93.892% |
| Piramal Pharma Limited | 24.47 Billion INR | 93.854% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -59.583% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 96.784% |
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 94.384% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 97.831% |
| Unichem Laboratories Limited | 4.86 Billion INR | 69.087% |
| Sequent Scientific Limited | 2.97 Billion INR | 49.512% |
| Novartis India Limited | 1.32 Billion INR | -13.34% |
| Wanbury Limited | 1.73 Billion INR | 13.101% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 63.526% |
| Wockhardt Limited | 16.24 Billion INR | 90.74% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -130.452% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 92.344% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 87.904% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 99.081% |
| Divi's Laboratories Limited | 32.44 Billion INR | 95.364% |
| NATCO Pharma Limited | 25.73 Billion INR | 94.156% |
| Gufic Biosciences Limited | 4.16 Billion INR | 63.915% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 67.169% |
| Ind-Swift Limited | 2.17 Billion INR | 30.776% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 73.987% |
| FDC Limited | 8.33 Billion INR | 81.956% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -680.329% |
| Granules India Limited | 16.79 Billion INR | 91.048% |
| Medicamen Biotech Limited | 495.49 Million INR | -203.515% |
| Alkem Laboratories Limited | 52.29 Billion INR | 97.124% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 75.832% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -10215.054% |
| Brooks Laboratories Limited | 65.62 Million INR | -2191.838% |
| Megasoft Limited | 342.07 Million INR | -339.647% |
| ZIM Laboratories Limited | 1.26 Billion INR | -18.709% |
| Strides Pharma Science Limited | 14.38 Billion INR | 89.548% |
| Neuland Laboratories Limited | 8.24 Billion INR | 81.766% |
| Morepen Laboratories Limited | 6.16 Billion INR | 75.591% |
| Hikal Limited | 3.14 Billion INR | 52.152% |
| Indoco Remedies Limited | 6.04 Billion INR | 75.106% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 74.21% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -142.379% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -113.743% |
| Hester Biosciences Limited | 1.27 Billion INR | -18.078% |